To the editor:

Human leukocyte antigen (HLA)–DPB1 functions as a classic transplantation antigen.1  In the context of hematopoietic stem cell transplantation (HSCT), when donor T cells recognize host HLA-DP, they can induce a graft-versus-host disease (GVHD) and/or a graft-versus-leukemia (GVL) effect, whereas in the opposite direction, host T cells recognizing the donor can induce rejection (HVG). Accordingly, any possibility to anticipate the nature and strength of an anti-DP T-cell response is crucial in this context.

Based on the HLA-DP recognition pattern of several HLA-DPB1*0901-specific T-cell clones, Crocchiolo et al classified HLA-DPB1 alleles according to their predicted “immunogenicity,”2  and using an algorithm deduced from this classification (Figure 1), they showed that the presence of “nonpermissive” HLA-DPB1 mismatches correlated with a significantly increased hazard of acute grade 2-IV GVHD. Unexpectedly, the authors reported that the increased risk of aGVHD was detectable independently of the predicted direction (GVH/GVL or HVG) of the T-cell response. To reconcile the statistical observation with the immunologic hypothesis (the increased risk of GVH when the algorithm predicted the recognition of donor HLA-DP by host T cells), these authors considered the possibility of an indirect pathway for GVH because of cytokine release by host T cells recognizing “immunogenic” HLA-DPB1 on donor antigen-presenting cells (APC).

Algorithm for permissiveness of HLA-DPB1 mismatches in donor-recipients pairs.2  Permissive and nonpermissive HLA-DPB1 disparity according to the algorithm described by Crocchiolo et al. aNumbers indicate the group of the 2 HLA-DPB1 alleles of the donor or the recipient. Group 1: DPB1*09:01,10:01,17:01; group 2: DPB1*03:01, 14:01, 45:01; group 3: DPB1*02:01, 0202, 0203; group 4: others.3  Immunogenicity decreases from group 1 to group 4.

Algorithm for permissiveness of HLA-DPB1 mismatches in donor-recipients pairs.2  Permissive and nonpermissive HLA-DPB1 disparity according to the algorithm described by Crocchiolo et al. aNumbers indicate the group of the 2 HLA-DPB1 alleles of the donor or the recipient. Group 1: DPB1*09:01,10:01,17:01; group 2: DPB1*03:01, 14:01, 45:01; group 3: DPB1*02:01, 0202, 0203; group 4: others.3  Immunogenicity decreases from group 1 to group 4.

Close modal

In 4 successive studies,3-6  we have in the past assessed the specificities of T-cell clones infiltrating skin biopsies during aGVHD (Table 1). In each situation, T-cell clones specific for host HLA-DP were isolated from the skin at the onset of aGVHD. These studies demonstrated that no mismatch could theoretically be considered as “permissive,” as confirmed in vitro by Rutten et al.7  The finding of up to a 10-fold difference observed between frequencies of T cells directed at a “permissive” versus “nonpermissive” DP mismatch, as argued by Sizzano et al,8  can hardly make a difference in the context of transplantation. T-cell frequency depends on the kinetics of the immune response and is a key physiologic factor in the race against an infection. In the present context of transplantation, the immune target (HLA-DP on host APC) remains present for weeks after the graft, and a 10-fold difference in frequency represents only 3-4 divisions for a T cell, which would take 1-2 days at most.

Nevertheless, a detailed analysis of anti-DP specificities remains particularly interesting and potentially useful (for example, to drive a GVL effect with DP-specific T-cell clones directed against an HLA-DP mismatch in the GVH direction, as we have previously proposed3,4,9 ). In line with HSCT, considering that “alloreactive TCR neither avoid contacting the bound peptide nor focus on the polymorphic residues that are exposed on the outer surface of the allo-MHC a-helices,”10  it would be of great interest to learn more about the set of endogenous peptides presented by HLA-DP alleles in hematopoietic and nonhematopoietic tissues. This may help to improve the targeting of anti-DP allogeneic reaction against the residual disease while avoiding the healthy tissues as much as possible.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Dr Henri Vié, Inserm, 8 Quai Moncousu, 44007 Nantes Cedex 1, France; e-mail: hvie@nantes.inserm.fr.

1
Shaw
 
BE
Mayor
 
NP
Russell
 
NH
et al. 
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles.
Leukemia
2010
, vol. 
24
 
1
(pg. 
58
-
65
)
2
Crocchiolo
 
R
Zino
 
E
Vago
 
L
et al. 
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation.
Blood
2009
, vol. 
114
 
7
(pg. 
1437
-
1444
)
3
Gaschet
 
J
Gallot
 
G
Ibisch
 
C
et al. 
Acute graft-versus-host disease after bone marrow transplantation with a single HLA-DPB1*1001 mismatch: involvement of different TCRBV subsets.
Bone Marrow Transplant
1998
, vol. 
22
 
4
(pg. 
385
-
392
)
4
Gaschet
 
J
Lim
 
A
Liem
 
L
et al. 
Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch.
J Clin Invest
1996
, vol. 
98
 
1
(pg. 
100
-
107
)
5
Gaschet
 
J
Mahe
 
B
Milpied
 
N
et al. 
Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.
J Clin Invest
1993
, vol. 
91
 
1
(pg. 
12
-
20
)
6
Gaschet
 
J
Trevino
 
MA
Cherel
 
M
et al. 
HLA-target antigens and T-cell receptor diversity of activated T cells invading the skin during acute graft-versus-host disease.
Blood
1996
, vol. 
87
 
6
(pg. 
2345
-
2353
)
7
Rutten
 
CE
van Luxemburg-Heijs
 
SA
van der Meijden
 
ED
et al. 
Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro [letter].
Blood
2010
, vol. 
115
 
1
(pg. 
151
-
153
)
8
Sizzano
 
F
Zito
 
L
Crivello
 
P
et al. 
Significantly higher frequencies of alloreactive CD4+ T cells responding to nonpermissive than to permissive HLA-DPB1 T-cell epitope disparities [letter].
Blood
2010
, vol. 
116
 
11
(pg. 
1991
-
1992
)
9
Ibisch
 
C
Gallot
 
G
Vivien
 
R
et al. 
Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation.
Bone Marrow Transplant
1999
, vol. 
23
 
11
(pg. 
1153
-
1159
)
10
Housset
 
D
Malissen
 
B
What do TCR-pMHC crystal structures teach us about MHC restriction and alloreactivity?
Trends Immunol
2003
, vol. 
24
 
8
(pg. 
429
-
437
)
Sign in via your Institution